The United States market has been flat over the last week but has shown a robust 11% rise over the past year, with earnings projected to grow by 15% annually in the coming years. In this climate, identifying stocks that are poised for growth yet remain underappreciated can offer unique opportunities for investors seeking to capitalize on these promising trends.
Name
Debt To Equity
Revenue Growth
Earnings Growth
Health Rating
FineMark Holdings
122.25%
2.34%
-26.34%
★★★★★★
Metalpha Technology Holding
NA
81.88%
-4.97%
★★★★★★
Senstar Technologies
NA
-20.82%
14.32%
★★★★★★
FRMO
0.09%
44.64%
49.91%
★★★★★☆
Valhi
43.01%
1.55%
-2.64%
★★★★★☆
China SXT Pharmaceuticals
64.25%
-29.05%
10.33%
★★★★★☆
Gulf Island Fabrication
19.65%
-2.17%
42.26%
★★★★★☆
Pure Cycle
5.11%
1.07%
-4.05%
★★★★★☆
Solesence
82.42%
23.41%
-1.04%
★★★★☆☆
Reitar Logtech Holdings
31.39%
231.46%
41.38%
★★★★☆☆
Click here to see the full list of 285 stocks from our US Undiscovered Gems With Strong Fundamentals screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Simply Wall St Value Rating: ★★★★★☆
Overview: Power Solutions International, Inc. designs, engineers, manufactures, markets, and sells engines and power systems across various regions globally and has a market cap of $1.40 billion.
Operations: PSIX generates revenue primarily from its Engineered Integrated Electrical Power Generation Systems, contributing $516.17 million.
Power Solutions International, a nimble player in the electrical industry, has made significant strides with its earnings growing 173.6% over the past year, outpacing the industry’s -8.9%. The company’s debt to equity ratio impressively fell from 258.1% to 131.3% in five years, reflecting better financial management. Trading at a price-to-earnings ratio of 17.2x, it offers good value compared to the broader US market’s 17.9x average. Recent earnings reports show robust growth with Q1 sales hitting US$135 million and net income reaching US$19 million, up from US$95 million and US$7 million respectively last year.
PSIX Earnings and Revenue Growth as at Jun 2025
Simply Wall St Value Rating: ★★★★★★
Overview: CorMedix Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States, with a market cap of $1.12 billion.
Weiterlesen
Operations: CorMedix’s financial data indicates no reported revenue segments, and the company’s market capitalization stands at approximately $1.12 billion.
CorMedix, a biopharmaceutical player, is making strides with its lead product, DefenCath, targeting life-threatening conditions. The company’s recent profitability marks a significant milestone as it reported net income of US$20.64 million in Q1 2025 compared to a US$14.47 million loss the previous year. Trading at 90% below estimated fair value and debt-free status further bolster its investment appeal despite shareholder dilution over the past year. Increased sales guidance for Q2 2025 to US$35-40 million reflects positive business developments and potential growth fueled by expanded clinical research and rising demand for dialysis-related infection prevention solutions.
CRMD Debt to Equity as at Jun 2025
Simply Wall St Value Rating: ★★★★★★
Overview: Pathward Financial, Inc. is a bank holding company for Pathward, National Association, offering a range of banking products and services in the United States with a market cap of approximately $1.79 billion.
Operations: Pathward Financial generates revenue primarily through its banking products and services. The company reported a net profit margin of 25.3% in the most recent period, indicating efficient cost management relative to its revenue streams.
Pathward Financial, with total assets of US$7 billion and equity of US$832 million, is making strategic moves to boost growth. Its allowance for bad loans stands at a robust 0.9% of total loans, supported by a primarily low-risk funding structure where 94% of liabilities are customer deposits. The company repurchased 575,804 shares this year for US$44.98 million as part of a larger buyback initiative. Although earnings grew by 8.8% annually over five years, recent insider selling and delayed SEC filings may raise some eyebrows among investors looking at this financial entity’s stability and future prospects.
CASH Earnings and Revenue Growth as at Jun 2025
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PSIX CRMD and CASH.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
